Innovations in healthcare delivery: Human papilloma virus self sampling diagnostics and participatory innovations for CCS

BACKGROUND: Human papillomavirus (HPV) infection is a major contributor to the development of cervical cancer, resulting in over 500,000 cases and 266,000 deaths annually worldwide. Previous cervical cancer screening programs have been successful in reducing cervical cancer rates, but have faced challenges such as low acceptance and adherence rates. Innovations in screening technology, such as the HerSwab self‐sampling test, have the potential to increase awareness, acceptance, and participation in cervical cancer screening programs. AIM: This literature review examines the effectiveness of HerSwab and participatory innovations in increasing adherence to cervical cancer screening. METHOD: This manuscript comprised a comprehensive narrative literature review encompassing the years 2006–2022. The review process adhered to the PRISMA diagram as a guiding framework. Among the search terms utilized, a total of 200 articles were initially retrieved. However, after applying the predefined inclusion criteria, only 57 articles were included. RESULTS: The HerSwab self‐sampling test is described, including how it is performed, challenges, and facilitators, and evaluation and assessment of its effectiveness. While the HerSwab diagnostic test is not currently widely available, studies should assess its feasibility in less developed countries where cervical cancer mortality rates are high. CONCLUSION: By increasing awareness and availability of innovative screening techniques, such as HerSwab, we can work toward reducing the incidence of cervical cancer and improving outcomes for women worldwide.